SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NKTR Drug delivery Company
NKTR 59.32+2.3%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (285)4/23/2008 10:33:30 AM
From: zax   of 507
 
Approved: Cimzia for Crohn's disease

8:02AM Nektar Therapeutics confirms FDA approval of Cimzia for Crohn's disease (NKTR) 4.74 : The co announces the FDA approved UCB's Cimzia for reducing the signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderate to severe active disease who have an inadequate response to conventional therapy. Under the terms of the agreement between Nektar and UCB, Nektar will receive manufacturing revenues and royalties on global sales of Cimzia for all indications.

------

My comment:

I hear you about the strong label, but frankly the warnings differ little in nature from those for Remicade or other TNF inhibitors. My feeling is that Cimzia has potential to be a blockbuster, especially as other approvals come through (i.e. Psoriasis, Psoriatic arthritis, etc.). With the stock quite depressed over the Exubera debacle I am adding to my position.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News